SIBN

+ Watchlist + Portfolio

SI-BONE, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $19.91
52-Week Range: $11.48 – $21.89
Market Cap: $873.07M
P/E (TTM): —
EPS (TTM): -0.32
Dividend Yield: —

Advanced Metrics

Price/Book: 4.77
PEG Ratio: —
Return on Equity: -8.30%
Return on Assets: -4.62%
Gross Margin: 79.53%
Operating Margin: -8.58%
Profit Margin: -6.85%
Current Ratio: 9.15
Debt/Equity: 0.23
Total Debt: $42.80M
Free Cash Flow: $-861.88K
Revenue Growth: 15.20%
Earnings Growth: —
Enterprise Value: $769.92M

SIBN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$106.41M	$138.89M	$167.18M	$200.93M
Cost of Revenue	$15.71M	$29.47M	$35.06M	$41.05M
Gross Profit	$90.70M	$109.42M	$132.12M	$159.88M
Research & Development	$13.63M	$15.03M	$16.56M	$17.45M
Selling, General & Admin	$136.69M	$141.32M	$150.81M	$164.76M
Operating Expenses	$150.31M	$156.35M	$167.37M	$182.21M
Operating Income	-$59.61M	-$46.93M	-$35.25M	-$22.33M
EBITDA	-$54.98M	-$34.45M	-$23.09M	-$10.51M
Pretax Income	-$61.26M	-$43.34M	-$30.91M	-$18.90M
Net Income	-$61.26M	-$43.34M	-$30.91M	-$18.90M
Diluted EPS	-1.79	-1.13	-0.75	-0.44
Diluted Shares	34.20M	38.43M	41.47M	42.96M

SIBN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.72M	$33.27M	$34.95M	$42.24M
Receivables	$20.67M	$21.95M	$27.46M	$29.91M
Inventory	$17.28M	$20.25M	$27.07M	$33.90M
Current Assets	$137.61M	$211.39M	$207.78M	$216.12M
Total Assets	$157.55M	$230.43M	$230.44M	$238.56M
Current Liabilities	$21.18M	$23.46M	$27.13M	$25.28M
Long-Term Debt	$35.17M	$36.06M	$35.45M	$35.57M
Total Debt	$39.43M	$38.99M	$37.48M	$36.69M
Total Liabilities	$59.25M	$61.05M	$63.47M	$61.02M
Retained Earnings	-$357.11M	-$400.44M	-$431.35M	-$450.26M
Shareholders' Equity	$98.30M	$169.38M	$166.96M	$177.53M
Working Capital	$116.43M	$187.94M	$180.65M	$190.84M
Net Debt	$14.45M	$2.79M	$504.00K	—

SIBN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$41.66M	-$18.71M	-$12.43M	-$675.00K
Capital Expenditure	-$9.51M	-$7.80M	-$10.50M	-$8.41M
Free Cash Flow	-$51.16M	-$26.51M	-$22.92M	-$9.09M
Depreciation & Amortisation	$3.45M	$5.43M	$4.38M	$5.77M
Stock-Based Compensation	$23.06M	$24.06M	$25.87M	$25.52M
Investing Cash Flow	-$2.81M	-$59.80M	$12.62M	$4.16M
Financing Cash Flow	$2.20M	$90.93M	$1.96M	$3.38M
Net Change in Cash	-$42.27M	$12.42M	$2.16M	$6.86M

SIBN Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$47.29M	$48.63M	$48.66M	$56.35M	$52.59M
Cost of Revenue	$9.60M	$9.82M	$9.81M	$11.82M	$10.64M
Gross Profit	$37.70M	$38.81M	$38.85M	$44.53M	$41.94M
Research & Development	$4.53M	$4.31M	$4.24M	$4.36M	$4.19M
Selling, General & Admin	$40.64M	$41.50M	$39.99M	$42.63M	$42.84M
Operating Expenses	$45.17M	$45.81M	$44.23M	$46.99M	$47.04M
Operating Income	-$7.48M	-$7.00M	-$5.38M	-$2.46M	-$5.09M
EBITDA	-$4.60M	-$4.12M	-$2.41M	$624.00K	-$2.13M
Pretax Income	-$6.54M	-$6.15M	-$4.57M	-$1.64M	-$4.33M
Net Income	-$6.54M	-$6.15M	-$4.57M	-$1.64M	-$4.33M
Diluted EPS	-0.15	-0.14	-0.11	-0.04	-0.10
Diluted Shares	42.34M	42.79M	43.19M	43.51M	43.96M

SIBN Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$41.19M	$34.15M	$26.49M	$42.24M	$33.53M
Receivables	$26.70M	$24.37M	$26.53M	$29.91M	$31.56M
Inventory	$30.38M	$34.24M	$35.73M	$33.90M	$35.53M
Current Assets	$204.20M	$207.45M	$210.78M	$216.12M	$214.72M
Total Assets	$227.28M	$230.92M	$234.27M	$238.56M	$242.72M
Current Liabilities	$23.95M	$24.75M	$26.44M	$25.28M	$21.49M
Long-Term Debt	$35.48M	$35.51M	$35.54M	$35.57M	$35.60M
Total Debt	$37.15M	$36.93M	$36.84M	$36.69M	$42.95M
Total Liabilities	$60.02M	$60.58M	$62.15M	$61.02M	$63.78M
Retained Earnings	-$437.90M	-$444.05M	-$448.61M	-$450.26M	-$454.59M
Shareholders' Equity	$167.26M	$170.34M	$172.13M	$177.53M	$178.94M
Working Capital	$180.25M	$182.70M	$184.34M	$190.84M	$193.23M
Net Debt	—	$1.36M	$9.05M	—	$2.06M

SIBN Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.91M	$173.00K	$2.33M	$1.73M	-$2.36M
Capital Expenditure	-$2.07M	-$2.10M	-$2.96M	-$1.29M	-$1.08M
Free Cash Flow	-$6.98M	-$1.93M	-$620.00K	$440.00K	-$3.44M
Depreciation & Amortisation	$1.28M	$1.37M	$1.49M	$1.64M	$1.62M
Stock-Based Compensation	$6.66M	$6.66M	$6.23M	$5.98M	$6.03M
Investing Cash Flow	$10.63M	-$9.47M	-$10.03M	$13.03M	-$6.23M
Financing Cash Flow	$103.00K	$2.23M	$11.00K	$1.03M	$34.00K
Net Change in Cash	$5.82M	-$7.07M	-$7.68M	$15.78M	-$8.56M

Market Snapshot

About

SI-BONE is a medical device company that pioneered the iFuse Implant System for minimally invasive surgical treatment of the sacroiliac joint. The company focuses on addressing a significant source of lower back pain that is often underdiagnosed. SI-BONE markets its products to spine surgeons and orthopedic specialists worldwide.